Larazotide

peptide · co-headlineInvestigational

Zonulin antagonist; tight-junction integrity

Summary

Zonulin antagonist / tight-junction regulator — the strongest human-data gut-barrier agent (celiac Phase 3). The mechanistic proof-of-concept behind the leaky-gut→autoimmunity hypothesis.

How it works

Zonulin antagonism → tight-junction integrity
↓ intestinal permeability

Dosing

unit: mg
frequency: TID before meals
standard dose: 0.5
administration route: Oral

Cycling

Course-based

Side effects

common: ["Well tolerated in trials"]

warnings: []

Verified citations

2 · PubMed-checked

Larazotide acetate: a pharmacological peptide approach to tight junction regulation.mechanismPMID 33881350 ↗
Tight junction regulation in celiac disease: focus on larazotide acetate.reviewPMID 26770266 ↗

Used for

Hashimoto'sPreclinical
IBD / leaky gutleadEmerging

Legal / compounding

Investigational

Legal status is a hard gate: non-compoundable or delisted agents cannot be filled and are blocked from protocol export. Keep 503A status current.